Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread

Camilo Ayala-Breton, Lukkana Suksanpaisan, Emily K. Mader, Stephen J Russell, Kah-Whye Peng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oncolytic viruses are structurally and biologically diverse, spreading through tumors and killing them by various mechanisms and with different kinetics. Here, we created a hybrid vesicular stomatitis/measles virus (VSV/MV) that harnesses the safety of oncolytic MV, the speed of VSV, and the tumor killing mechanisms of both viruses. Oncolytic MV targets CD46 and kills by forcing infected cells to fuse with uninfected neighbors, but propagates slowly. VSV spreads rapidly, directly lysing tumor cells, but is neurotoxic and loses oncolytic potency when neuroattenuated by conventional approaches. The hybrid VSV/MV lacks neurotoxicity, replicates rapidly with VSV kinetics, and selectively targets CD46 on tumor cells. Its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51.

Original languageEnglish (US)
Pages (from-to)1930-1937
Number of pages8
JournalMolecular Therapy
Volume21
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Oncolytic Viruses
Safety
Neoplasms
Measles virus
Vesicular Stomatitis
Heterografts
Viruses

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. / Ayala-Breton, Camilo; Suksanpaisan, Lukkana; Mader, Emily K.; Russell, Stephen J; Peng, Kah-Whye.

In: Molecular Therapy, Vol. 21, No. 10, 10.2013, p. 1930-1937.

Research output: Contribution to journalArticle

@article{d37a7a300e7d4885941b9add47e94dd1,
title = "Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread",
abstract = "Oncolytic viruses are structurally and biologically diverse, spreading through tumors and killing them by various mechanisms and with different kinetics. Here, we created a hybrid vesicular stomatitis/measles virus (VSV/MV) that harnesses the safety of oncolytic MV, the speed of VSV, and the tumor killing mechanisms of both viruses. Oncolytic MV targets CD46 and kills by forcing infected cells to fuse with uninfected neighbors, but propagates slowly. VSV spreads rapidly, directly lysing tumor cells, but is neurotoxic and loses oncolytic potency when neuroattenuated by conventional approaches. The hybrid VSV/MV lacks neurotoxicity, replicates rapidly with VSV kinetics, and selectively targets CD46 on tumor cells. Its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51.",
author = "Camilo Ayala-Breton and Lukkana Suksanpaisan and Mader, {Emily K.} and Russell, {Stephen J} and Kah-Whye Peng",
year = "2013",
month = "10",
doi = "10.1038/mt.2013.164",
language = "English (US)",
volume = "21",
pages = "1930--1937",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread

AU - Ayala-Breton, Camilo

AU - Suksanpaisan, Lukkana

AU - Mader, Emily K.

AU - Russell, Stephen J

AU - Peng, Kah-Whye

PY - 2013/10

Y1 - 2013/10

N2 - Oncolytic viruses are structurally and biologically diverse, spreading through tumors and killing them by various mechanisms and with different kinetics. Here, we created a hybrid vesicular stomatitis/measles virus (VSV/MV) that harnesses the safety of oncolytic MV, the speed of VSV, and the tumor killing mechanisms of both viruses. Oncolytic MV targets CD46 and kills by forcing infected cells to fuse with uninfected neighbors, but propagates slowly. VSV spreads rapidly, directly lysing tumor cells, but is neurotoxic and loses oncolytic potency when neuroattenuated by conventional approaches. The hybrid VSV/MV lacks neurotoxicity, replicates rapidly with VSV kinetics, and selectively targets CD46 on tumor cells. Its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51.

AB - Oncolytic viruses are structurally and biologically diverse, spreading through tumors and killing them by various mechanisms and with different kinetics. Here, we created a hybrid vesicular stomatitis/measles virus (VSV/MV) that harnesses the safety of oncolytic MV, the speed of VSV, and the tumor killing mechanisms of both viruses. Oncolytic MV targets CD46 and kills by forcing infected cells to fuse with uninfected neighbors, but propagates slowly. VSV spreads rapidly, directly lysing tumor cells, but is neurotoxic and loses oncolytic potency when neuroattenuated by conventional approaches. The hybrid VSV/MV lacks neurotoxicity, replicates rapidly with VSV kinetics, and selectively targets CD46 on tumor cells. Its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51.

UR - http://www.scopus.com/inward/record.url?scp=84885023559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885023559&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.164

DO - 10.1038/mt.2013.164

M3 - Article

C2 - 23842448

AN - SCOPUS:84885023559

VL - 21

SP - 1930

EP - 1937

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 10

ER -